24
UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Embed Size (px)

Citation preview

Page 1: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

 UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug

Suberoylanilide Hydroxamic Acid (SAHA,vorinostat)

Ishita Patel

Page 2: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Presentation Outline

[1] Motivation for Research a. Histone Deacetylases Inhibitors

b. The function of Nitric Oxide (NO) in the immune system

[2] Summary of Research Goals

[4] Establishing a working Protocol

[5] Results

[6] Discussion

Page 3: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Histone deacetylase inhibition

acetyl groups = shields

positively charged amine groupsLysine, arginine = green spheres

Hyperacetylated chromatin

is transcriptionally active

Hypoacetylated chromatin

is transcriptionally silent

CANCER = altered gene transcription and increased cell survival

Page 4: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

HDAC8

SAHA structural analogs inhibit the function Of Zinc-dependent histone deacetylase

Page 5: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Structural Features of Hybrid Polar Compounds

cap group

interacts with the rim of the catalytic tunnel

hydrophobic spacer

allows the molecule to lie into the catalytic tunnel

zinc-binding group

complexes the zinc ion at bottom of catalytic cavity.

(SAHA)

Page 6: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

[1] SAHA and HPCs Have Hydroxamate group at the end

[2] Hydroxamates are known to release NO

[3] Is NO release by HPCs important?

Page 7: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Physiological effect of NO

Page 8: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Research goals

[1] Experimental set up optimization

a) Check reproducibility of NanoDrop Spectrometer b) Working with the Griess reagent c) Determining Optimal Reactant Concentration

[2] NO release upon oxidation by metMb/H2O2 for each of the HPCs used

[3] What structural and chemical features of the different HPCs make these rates different?

Page 9: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

The Kinetic Assay for NO production

Reaction mixture

[1] Hydroxamate: 250 µM

[2] H2O2: 5 mM

[3] Met Myoglobin: 10 µM

Sample the reaction at different time pointsAdd Catalase to stop the reaction…then…

Add both components of the Griess System

Page 10: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

NO Production: Oxidation of Hydroxamates

Page 11: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

The Griess Reaction

Page 12: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Color Development time for Griess Reaction

500 µL of 100 µM sodium nitrite250 µL of Solution A250 µL of solution B

Page 13: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Standard Curve for the Griess reagent

200 µL of 20 - 250 µM sodium nitrite100 µL of Solution A100 µL of solution B

Page 14: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

How reproducible are the measurements of the NanoDrop Spectrometer?

The noise level (Error) does not get larger than 5% and all the rates of NO production are reproducible as can be seen from the overlay of trials A+B+C

Is this the best way to analyze small samples of hard to obtain chemicals?

The NanoDrop gives reproducible results and the sample volumes were as low as 200 µL. For samples that are expensive or in short supply, the NanoDrop is the best choice.

Page 15: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Results

Page 16: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel
Page 17: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel
Page 18: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel
Page 19: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel
Page 20: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Nitric Oxide Production as a function of time

Page 21: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

NO release rates for the HPCs used

NO production rates have error bars of +/- 0.002 µM per min (Standard Deviation of the Mean)

Page 22: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

Hydroxy Urea has the fastest NO release rate

SAHA has the slowest NO release rate

[1] The trend is that the larger molecules will have slower oxidation rates.

[2] The Hydroxamide has to make contact with the HEME group inside Myoglobin, the smaller molecules have easier access to the HEME group.

What structural and chemical features of the different HPCs make these rates different?

Page 23: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

SAHA has the slowest NO release rate. SAHA is also the best anticancer drug of the compounds studied here

The conclusion is that NO release is not the primary function of SAHA.

The main function of SAHA is Histone deacetylase inhibition

The relatively slow NO release rate means that SAHA is more resistant to oxidation

This would enable SAHA to remain in the body for longer periods of time, requiring fewer doses of the drug to be administered to cancer patients.

CONCLUSIONS

Page 24: UV-Vis Spectrometric Quantification of Nitric Oxide Production by the Anticancer Drug Suberoylanilide Hydroxamic Acid (SAHA,vorinostat) Ishita Patel

I would like to express my sincere gratitude to the members of my thesis committee:

Prof. Paul Dominguez Prof. Anthony Capetandes Prof. Uri Samuni

Prof. Jorge Ramos